Peregrine Capital Management LLC Sells 18,147 Shares of Artivion, Inc. $AORT

Peregrine Capital Management LLC reduced its holdings in shares of Artivion, Inc. (NYSE:AORT) by 5.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 295,721 shares of the company’s stock after selling 18,147 shares during the quarter. Peregrine Capital Management LLC owned about 0.62% of Artivion worth $13,488,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of AORT. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Artivion during the third quarter worth $27,000. Aster Capital Management DIFC Ltd grew its position in shares of Artivion by 402.3% in the third quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock valued at $27,000 after purchasing an additional 519 shares in the last quarter. USA Financial Formulas raised its stake in shares of Artivion by 163.5% during the 4th quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock valued at $52,000 after purchasing an additional 703 shares during the period. KBC Group NV bought a new stake in shares of Artivion during the 4th quarter valued at $65,000. Finally, First Horizon Corp lifted its holdings in Artivion by 199.4% during the 4th quarter. First Horizon Corp now owns 1,602 shares of the company’s stock worth $73,000 after purchasing an additional 1,067 shares in the last quarter. 86.37% of the stock is currently owned by hedge funds and other institutional investors.

Artivion Price Performance

Shares of AORT traded up $0.43 during trading hours on Thursday, reaching $36.99. 7,175 shares of the company’s stock traded hands, compared to its average volume of 416,903. Artivion, Inc. has a 12 month low of $23.04 and a 12 month high of $48.25. The company has a current ratio of 3.53, a quick ratio of 2.62 and a debt-to-equity ratio of 0.49. The stock has a market cap of $1.79 billion, a PE ratio of 185.63 and a beta of 1.63. The firm’s 50 day simple moving average is $36.73 and its 200-day simple moving average is $41.50.

Artivion (NYSE:AORT) last posted its quarterly earnings data on Thursday, February 12th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.03. Artivion had a net margin of 2.21% and a return on equity of 7.43%. The company had revenue of $118.30 million for the quarter, compared to analysts’ expectations of $116.42 million. Artivion’s revenue for the quarter was up 19.2% on a year-over-year basis. Equities analysts expect that Artivion, Inc. will post 0.63 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Canaccord Genuity Group reduced their target price on Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a report on Friday, February 13th. Weiss Ratings upgraded shares of Artivion from a “sell (d)” rating to a “hold (c-)” rating in a research report on Friday, February 20th. Needham & Company LLC reaffirmed a “buy” rating on shares of Artivion in a research note on Monday. Stifel Nicolaus set a $55.00 target price on shares of Artivion in a report on Thursday, March 5th. Finally, Wall Street Zen upgraded shares of Artivion from a “hold” rating to a “buy” rating in a research note on Saturday, April 11th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $51.00.

Insider Activity

In other Artivion news, EVP Lance A. Berry sold 6,316 shares of the company’s stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $37.78, for a total value of $238,618.48. Following the completion of the sale, the executive vice president owned 210,827 shares of the company’s stock, valued at $7,965,044.06. This represents a 2.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Marshall S. Stanton sold 2,149 shares of Artivion stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $37.78, for a total transaction of $81,189.22. Following the transaction, the senior vice president directly owned 60,097 shares in the company, valued at $2,270,464.66. This trade represents a 3.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 133,043 shares of company stock worth $4,977,158. Corporate insiders own 6.30% of the company’s stock.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.